WO1999032147A1 - Immunization for ebola virus infection - Google Patents
Immunization for ebola virus infection Download PDFInfo
- Publication number
- WO1999032147A1 WO1999032147A1 PCT/US1998/027364 US9827364W WO9932147A1 WO 1999032147 A1 WO1999032147 A1 WO 1999032147A1 US 9827364 W US9827364 W US 9827364W WO 9932147 A1 WO9932147 A1 WO 9932147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- virus
- promoter
- pharmaceutical composition
- ebola virus
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title claims abstract description 36
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 title abstract description 22
- 238000002649 immunization Methods 0.000 title description 30
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 75
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 75
- 229960005486 vaccine Drugs 0.000 claims abstract description 69
- 241001115402 Ebolavirus Species 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 40
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 102000011931 Nucleoproteins Human genes 0.000 claims abstract 4
- 108010061100 Nucleoproteins Proteins 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 10
- 241001115401 Marburgvirus Species 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 7
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 abstract description 26
- 108010067390 Viral Proteins Proteins 0.000 abstract description 16
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract description 4
- 239000013612 plasmid Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 31
- 239000013598 vector Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 21
- 241000700198 Cavia Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000711950 Filoviridae Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000011597 hartley guinea pig Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108090000197 Clusterin Proteins 0.000 description 2
- 102000003780 Clusterin Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- -1 DDA Substances 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates generally to viral vaccines and, more particularly, to Ebola virus vaccines and methods of protecting against disease caused by infection with Ebola virus.
- Ebola viruses and the genetically-related Marburg virus, are filoviruses associated with outbreaks of highly lethal hemorrhagic fever in humans and primates in North America, Europe, and Africa.
- Ebola viruses are negative-stranded RNA viruses comprised of four subtypes, including those described in the Zaire, Sudan, Reston, and Ivory Coast episodes. Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996). Although several subtypes have been defined, the genetic organization of these viruses is similar, each containing seven linearly arrayed genes.
- the envelope glycoprotein exists in two alternative forms, a 50-70 kilodalton (kDa) secreted protein of unknown function encoded by the viral genome and a 130 kDa transmembrane glycoprotein generated by RNA editing that mediates viral entry. Peters, CJ.
- Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided.
- the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP).
- the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP).
- the nucleic acid molecule encodes the viral nucleoprotein (NP).
- the present invention also provides methods for immunizing a subject against disease caused by infection with Ebola virus comprising administering to the subject an immunoeffective amount of an Ebola virus vaccine.
- Administration can be by any of the routes normally used for gene therapy.
- the Ebola virus vaccine is administered by intramuscular injection.
- the genetic immunization methods of the present invention provide protective immunity against disease caused by infection with Ebola virus.
- Figures 1A and 1 B are photographs showing expression of Ebola virus gene products in eukaryotic plasmid expression vectors.
- Figure 1A Expression vectors encoding the indicated viral gene products under regulation of the CMV immediate-early region 1 enhancer and promoter were prepared and transfected into 293 cells as previously described. Manthorpe, M. et al. Hum. Gene. Ther. 4:419-431 (1993); Sambrook, J., Fritch, E.F., & Maniatis, T. Cold Spring Harbor, N.Y. Cold Spring Laboratory Harbor Press, 1994.
- Cell extracts were prepared and analyzed by Western blot analysis for NP (left) or GP (right) using relevant rabbit antisera and a secondary antibody, horseradish peroxidase conjugated donkey anti-rabbit IgG of a dilution of 1 :5,000. Incubation with primary antibody was for 30 minutes at room temperature, and for 30 minutes at room temperature with secondary antibody. Immunocomplexes were then detected by chemiluminescence using super signal substrate reagents (Pierce) according to manufacturer's instructions.
- FIG 1B Generation of antibody response in mice immunized with the indicated vectors and analyzed by Western blot for NP, GP, and sGP as shown. Antisera from mice were tested at a dilution of 1 :500 (NP), 1 :50 (GP), or 1 :50 (sGP), respectively, and developed with a secondary antibody (sheep anti-mouse, 1 :5,000, Amersham Life Science) and chemiluminescence as in Figure 1 A.
- the control vector used for immunization represents the expression vector plasmid with no insert. Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431 (1993).
- Figures 2A-2D are graphs showing the immune responses to NP and GP after genetic immunization in mice.
- FIG. 2A Splenic lymphocytes from vector or NP-plasmid immunized mice were isolated approximately 6 weeks after the initial immunization and sensitized in vitro for 5 days with 10 U/ml hlL-2. Renca-NP cells sensitized splenocytes from vector-immunized or pCMV-NP immunized mice were used to detect CTL activity at the indicated effectortarget ratios on Renca or Renca-NP cells (left, middle) or with allogeneic effector cells with Renca-NP to show that they are susceptible to lysis (right).
- Allogeneic effector cells were generated by incubating cells derived from mice with a C57BI/6 background (5x10 ⁇ /ml) with irradiated Balb/c spleen cells (5x10 6 /ml) in the presence of IL-2 (20 U/ml) for five days.
- the chromium release CTL assay with Renca-NP cells was performed in triplicate as previously described. Ohno, T. et al., Gene. Ther. 4:361-366 (1997).
- FIG. 2B Balb/C female mice were immunized with the sGP plasmid expression vector and analyzed for their ability to lyse the syngeneic Renca cell line stably expressing GP. Isolation of stable transfectants, confirmation of expression, and CTL assay were performed as described (see. Specific Example, II. Methods). Renca-GP or sGP sensitized splenocytes from pCMV-GP or pCMV-sGP immunized mice were used to determine the specific killing of 51 chromium labeled Renca-GP cells at the indicated E/T ratios.
- Figure 2C Mice immunized with GP were analyzed for their ability to lyse a syngeneic CT26 cell stably expressing GP or CT26 vector control transduced line at the indicated E/T ratios.
- FIG. 2D Cellular proliferative response in the indicated immunized mice. T cells, enriched or depleted (see, Specific Example, II. Methods), were incubated at
- Figures 3A-3C are graphs showing immunization with sGP or GP expression plasmids induces T cell responses to sGP in guinea pigs.
- FIGS 3A-3C Cell-mediated immunity in guinea pigs was analyzed by performing assays to detect cell proliferation to control or GP antigen (A) or T-cell growth factor production in response to the indicated antigens.
- the culture supematants containing these antigens were prepared as previously described (Bottomly, K. et al., Measurement of human and murine interleukin 2 and interleukin 4. in Current Protocols in Immunology, (eds., Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M.& Strober, W.) 6.3.1-6.3.12 (New York, John Wiley & Sons, Inc. 1992); Arai, H.
- cell numbers refer to the concentration of spleen cells per ml in the 3 H-thymidine proliferation assay.
- B supematants from A, harvested at the time of the peak proliferative response to sGP, were incubated with primary guinea pig T cells maintained in 200 U/ml of human IL-2.
- the percent maximal response refers to the magnitude of stimulation in response to the indicated stimuli relative to supematants from 24 hour concanaval (in A-stimulated cells (2 ⁇ g/ml)).
- the requirement of T lymphocytes in guinea pig spleen cells for the proliferative response to sGP performed as described in Specific Example, II. Methods, is shown (C).
- Figures 4A-4F are photographs showing the immunohistochemical analysis of Ebola virus antigens in liver, lung, and spleen from representative protected (GP- animal 3) or infected (vector-animal 2) guinea pigs.
- FIGS. 4A-4F Magnification: liver, 40x; lung, 20x; spleen, 20x.
- Figure 5 is a schematic of the plasmid pVR 1012-GP(IC) (Ivory Coast strain of GP, SEQ ID NO: 1 ).
- Figure 6 is a schematic of the plasmid pVR 1012-GP(S) (Sudan strain of GP, see SEQ ID NO: 2).
- Figure 7 is a schematic of the plasmid pVR 1012-GP(Z) (Zaire strain of GP, see SEQ ID NO: 3).
- Figure 8 is a schematic of the plasmid pVR 1012-sGP(Z) (Zaire strain of sGP, see SEQ ID NO: 4).
- Figure 9 is a schematic of the plasmid pVR 1012-NP.
- Ebola virus vaccines comprising a nucleic acid molecule encoding an Ebola viral protein operatively-linked to a control sequence in a pharmaceutically acceptable carrier.
- the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP).
- the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP).
- the nucleic acid molecule encodes the viral nucleoprotein (NP).
- the present invention further includes vaccines comprising nucleic acid molecules encoding Ebola viral proteins other than GP, sGP, and NP, e.g., other structural gene products which elicit protective immunity from disease caused by infection with Ebola virus.
- the nucleic acid molecules of the vaccines of the present invention encode structural gene products of any Ebola viral strain including the Zaire, Sudan, Ivory Coast and Reston strains. Nucleic acid molecules encoding structural gene products of the genetically-related Marburg virus strains may also be employed.
- nucleic acid molecules of the present invention may be modified, e.g., the nucleic acid molecules set forth herein may be mutated, as long as the modified expressed protein elicits protective immunity from disease caused by infection with Ebola virus.
- the nucleic acid molecule may be mutated so that the expressed protein is less toxic to cells.
- the present invention also includes vaccines comprising a combination of nucleic acid molecules.
- nucleic acid molecules encoding GP, sGP and NP of the Zaire, Sudan and Ivory Coast Ebola strains may be combined in any combination, in one vaccine composition.
- the present invention also provides methods for immunizing a subject against disease caused by infection with Ebola virus comprising administering to the subject an immunoeffective amount of an Ebola virus vaccine.
- Methods of making and using Ebola virus vaccines are also provided by the present invention including the preparation of pharmaceutical compositions.
- the term "encoding" is intended to mean that the subject nucleic acid may be transcribed in a cell, e.g., when the subject nucleic acid is linked to appropriate control sequences such as a promoter in a suitable vector (e.g., an expression vector) and the vector is introduced into a cell.
- the nucleic acid molecules of the present invention may be DNA molecules, cDNA molecules or RNA molecules, and are preferably cDNA molecules.
- operatively-linked refers to functional linkage between a nucleic acid expression control sequence (such as a promoter) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
- Expression control sequences are known to those skilled in the art (see, e.g., Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990)).
- Vectors which contain both a promoter and a cloning site to which an inserted piece of nucleic acid is operatively-linked to the promoter are well known in the art and are generally referred to herein as "expression vectors" or "expression vector plasmids".
- these vectors are capable of transcribing nucleic acid in vitro and in vivo.
- a preferred vector is the cytomegalovirus (CMV) expression vectorwhich directs high levels of gene expression in muscle.
- CMV cytomegalovirus
- Nucleic acid molecules which hybridize under stringent conditions to the nucleic acid molecules described herein are also within the scope of the present invention. As will be appreciated by those skilled in the art, multiple factors are considered in determining the stringency of hybridization including species of nucleic acid, length of nucleic acid probe, T m (melting temperature), temperature of hybridization and washes, salt concentration in the hybridization and wash buffers, aqueous or formamide hybridization buffer, and length of time for hybridization and for washes.
- stringent conditions are DNA-DNA hybridization with a probe greater than 200 nucleotides in 5 x SSC, at 65°C in aqueous solution or 42°C in formamide, followed by washing with 0.1 x SSC, at 65°C in aqueous solution.
- a probe greater than 200 nucleotides in 5 x SSC at 65°C in aqueous solution or 42°C in formamide
- washing with 0.1 x SSC at 65°C in aqueous solution.
- administration of the vaccines of the present invention can be by any of the routes normally used for gene therapy.
- administration is by intramuscular injection, however, other procedures for transfecting cells may also be employed, such as transfection using calcium phosphate coprecipitation, liposome-mediated transfection, plasmid and viral vector- mediated transfection and DNA protein complex-mediated transfection.
- Viral vector- mediated transfection includes, without limitation, the use of retroviral, replication- deficient retroviral, adenoviral and adeno-associated viral vectors. Cells transfected by the vaccines in the context of ex vivo gene therapy can also be administered.
- the vaccines of the present invention may be employed in combination with traditional immunization approaches such as employing protein antigens, vaccinia virus and inactivated virus, as vaccines.
- the vaccines of the present invention are administered to a subject (the subject is "primed” with a vaccine of the present invention) and then a traditional vaccine is administered (the subject is "boosted” with a traditional vaccine).
- a traditional vaccine is first administered to the subject followed by administration of a vaccine of the present invention.
- a traditional vaccine and a vaccine of the present invention are co-administered.
- Immunogenicity may be significantly improved if the vaccines of the present invention are co-administered with an immunostimulatory agent or adjuvant.
- Adjuvants enhance immunogenicity but are not necessarily immunogenic themselves. Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Adjuvants may thus be employed to enhance the immunogenicity of the vaccines of the present invention, as well as the immunogenicity of traditional vaccines.
- Suitable adjuvants are well known to those skilled in the art and include, without limitation, aluminum phosphate, aluminum hydroxide, QS21 , Quil A, derivatives and components thereof, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, polyphosphazene, a lipoprotein, ISCOM matrix, DC-Chol, DDA, and other adjuvants and bacterial toxins, components and derivatives thereof.
- the vaccines of the present invention may also be co-administered with cytokines to further enhance immunogenicity.
- the cytokines may be administered by methods known to those skilled in the art, e.g., as a nucleic acid molecule in plasmid form or as a protein or fusion protein.
- the immune system of the host Upon inoculation with a pharmaceutical composition as described herein, the immune system of the host responds to the vaccine by producing antibodies, both secretory and serum, specific for Ebola virus proteins.
- the host becomes at least partially or completely immune to Ebola virus infection, or resistant to developing moderate or severe disease caused by Ebola virus infection.
- compositions comprising the nucleic acid molecules encoding
- Ebola viral proteins described herein, either alone or in combination, and a pharmaceutically acceptable carrier are also provided by the present invention.
- pharmaceutically acceptable carrier encompasses any of the standard pharmaceutical carriers, such as those suitable for parenteral administration, such as, for example, by intramuscular, intraarticular (in the joints), intravenous, intradermal, intraperitoneal, and subcutaneous routes.
- formulations include aqueous and non-aqueous, isotonic sterile injection solutions, which contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non- aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the vaccine dissolved in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the vaccine, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; (d) suitable emulsions; and (e) polysaccharide polymers such as chitians.
- the vaccine alone or in combination with other suitable components, may also be made into aerosol formulations to be administered via inhalation, e.g., to the bronchial passageways. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
- Suitable formulations for rectal administration include, for example, suppositories, which consist of the vaccine with a suppository base.
- Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the vaccine with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the recipient, e.g., the patient.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules or vials and may be prepared by any method known in the art.
- compositions comprising any of the nucleic acid molecules encoding Ebola viral proteins of the present invention are useful to immunize a subject against disease caused by Ebola virus infection.
- this invention further provides methods of immunizing a subject against disease caused by Ebola virus infection, e.g., hemorrhagic fever, comprising administering to the subject an immunoeffective amount of a pharmaceutical composition of the invention.
- This subject may be an animal, for example a mammal, such as a primate or preferably a human.
- the vaccines of the present invention are also suitable for veterinary immunization.
- the vaccines of the present invention comprising nucleic acid molecules encoding Ebola virus structural gene products from the Reston strain, which is known to infect animals, are particularly useful in such veterinary immunization methods.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, immunogenic and protective.
- the quantity to be administered depends on the subject to be treated, including, for example, the capacity of the immune system of the individual to synthesize antibodies, and, if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and may be monitored on a patient-by-patient basis.
- suitable dosage ranges are readily determinable by one skilled in the art and generally range from about 300 ⁇ g to about 4-5 mg.
- the dosage may also depend, without limitation, on the route of administration, the patient's state of health and weight, and the nature of the formulation.
- nucleic acid molecules encoding Ebola viral proteins of the present invention may be combined with nucleic acid molecules encoding other viral proteins of other virus strains to achieve protection against multiple strains of Ebola virus.
- the vaccines will be in an admixture and administered simultaneously, but may also be administered separately.
- the vaccine compositions of the present invention can be administered simultaneously, separately or sequentially with other genetic immunization vaccines such as those for influenza (Ulmer, J.B. et al., Science 259:1745-1749 (1993); Raz, E. et al., PNAS (USA) 91 :9519-9523 (1994)), malaria (Doolan, D.L. et al., J. Exp. Med. 183:1739-1746 (1996); Sedegah, M. et al., PNAS (USA) 91 :9866-9870 (1994)), and tuberculosis (Tascon, R.C. et al., Nat Med. 2:888-892 (1996)).
- influenza Ulmer, J.B. et al., Science 259:1745-1749 (1993); Raz, E. et al., PNAS (USA) 91 :9519-9523 (1994)
- malaria Doolan, D.L. et al.
- single or multiple administrations of the vaccine compositions of the present invention may be carried out.
- subjects who are particularly susceptible to Ebola virus infection may require multiple immunizations to establish and/or maintain protective immune responses.
- Levels of induced immunity can be monitored by measuring amounts of neutralizing secretory and serum antibodies, and dosages adjusted or vaccinations repeated as necessary to maintain desired levels of protection.
- kits comprising the vaccines of the present invention.
- kits comprising a vaccine and instructions for use are within the scope of this invention.
- the vaccines and methods of the present invention evoke a protective immune response and do not lead to immunopotentiation or exacerbated disease.
- the vaccines lack transmissibility, are genetically stable and induce protective levels of humoral and cell-mediated immunity.
- eukaryotic expression vector plasmids were injected into mice.
- the cytomegalovirus (CMV) immediate early region 1 enhancer was used to stimulate transcription because it directs high levels of gene expression in muscle.
- CMV cytomegalovirus
- cDNAs encoding an abundant structural protein, the major viral nucleocapsid phosphoprotein (NP), the secreted glycoprotein (sGP), or the membrane-associated glycoprotein (GP) were inserted.
- plasmids were injected into mice to characterize their ability to induce humoral and cellular immune responses to the relevant viral proteins.
- An antibody response to the viral NP gene product was readily detectable (Fig. 1 B), with titers of ⁇ 1 :16,000 by Western blot analysis. The titer of antibody induced in response to injection with plasmids encoding the viral glycoproteins was lower.
- guinea pigs were challenged four months after the initial immunization (Table 1 B).
- all animals immunized with the control vector succumbed to infection within a week after virus challenge (n 4).
- antibody titers were lower, and three of the four guinea pigs immunized with NP succumbed to infection, with the single survivor appearing severely ill after 1 week, in contrast to the protective response with NP at the earlier time point after immunization in Group I.
- More effective protection was seen in animals immunized with vector expressing GP, protection was noted in four of five animals challenged, with one survivor appearing weak but surviving the viral challenge.
- guinea pigs injected with GP or sGP plasmids were able to generate cell-mediated immune responses to the viral glycoprotein in addition to the antibody response. These responses were antigen-specific and T cell-dependent, as detected in sGP antigen-dependent spleen cell proliferation and T-cell growth factor assays (Fig. 3A-C).
- Fig. 3A-C T cell growth factor assays
- Guinea pigs were immunized on days 1, 14, 28, 42, and challenged on day 62.
- the surviving NP immunized animal (4) was found to have significant levels of virus in major organs by immunohistochemistry, and more than 5 logs of virus was detected in the serum and spleen, in contrast to GP and sGP animals where no virus was detected.
- Virus load correlated with susceptibility to infection with titers of > 10 5 in infected animals compared to undetectable levels in immunized survivors.
- the liver, lung, and spleen showed evidence of significant viral antigen by immunohistochemistry (Fig. 4, Table 1), and both reticuloendothelial and mononuclear phagotic involvement was observed.
- Plasmids Plasmids containing the GP, sGP, or NP cDNAs (Sanchez, A. et al., Virus. Res. 29:215-240 (1993), Genbank) were used to subclone the relevant inserts into CMV expression vectors which utilized the bovine growth hormone polyadenylation sequence. Manthorpe, M. et a I., Hum.
- plasmid pGEM-3Zf(-)-GP was digested with EcoR I, treated with the Klenow fragment of E. coli DNA polymerase, and digested with BamH I. The GP fragment was then inserted into the pCMV expression vector plasmid digested with BamH I, Klenow fragment and Bgl II.
- the plasmid pCRII-sGP was digested with EcoR I, treated with Klenow enzyme, and the resulting fragment inserted into the BamH l/Bgl II CMV plasmid which had been incubated with Klenow fragment, calf intestinal phosphatase (CIP), then phenol chloroform extract.
- CIP calf intestinal phosphatase
- plasmid pSP64-NP2 (Sanchez, A. et al., Virology 170:81-91 (1989)) was digested with EcoR I, treated with Klenow enzyme, and digested with BamH I.
- the NP insert was cloned into CMV treated with BamH I, Klenow enzyme, followed by heat inactivation and Bgl II digestion.
- Viral challenge in guinea pigs Animals were immunized by injection of 100 ⁇ (0.5 mg/ml) in each hind leg (two injections at each time point) with the indicated plasmid expression vectors. Animals were challenged by inoculation with a stock of Ebola virus (Zaire, 1976) that had been passaged once in vero E6 cells and serially passaged by intraperitoneal injection of spleen homogenates in Hartley guinea pigs seven times.
- Ebola virus Zaaire, 1976
- Immunized guinea pigs were injected intrapehtoneally with 0.5 ml of a 1 :1 ,000 dilution of spleen cell homogenate in Hank's balanced salt solution 122 days after the initial plasmid DNA injection (1000 pfu). Survival was determined 10 days later at which times animals were sacrificed for serologic and pathologic analysis.
- ELISA enzyme-linked immunosorbent assay (Volchkov, V.E. et al., FEBS. Lett. 305:181-184 (1992); Sanchez, A. et al., Virus. Res. 29:215-240 (1993)) on infected cell supematants and enriched viral extracts containing GP, sGP, or NP were performed as previously described. III. DISCUSSION
- the immune response to selected Ebola virus proteins after genetic immunization in mice was analyzed and their ability to protect against lethal infection in a susceptible animal model, the guinea pig, was tested.
- the immune analyses performed in different species suggest similar patterns of response, though the specific peptides which may be recognized by the immune system to confer protection in the guinea pig could differ from the mouse. Because the principles of MHC antigen presentation and recognition apply broadly across species (Monaco, J.J., Immunol. Today 13:173-179 (1992); Jorgensen, J.L. et al., Annu. Rev. Immunol. 10:835-873 (1992); Zinkemagel, R.M. et al., Immunol. Today 18:14-17 (1997)), the finding that protection was observed in different members of an outbred strain and that similar immune responses were seen in different species is not unexpected and suggests that this approach may be applicable to humans.
- Vaccines against arenaviruses and filoviruses in New Generation Vaccines, (eds., Levine, M.M., Woodrow, G.C., Kaper, J.B.& Cobon, G.S.) 749-765 (New York, NY, Marcel Dekker, Inc. 1997). It is likely that traditional immunization approaches using protein antigens, vaccinia virus, or inactivated virus do not allow for appropriate uptake and presentation of viral antigens by dendritic or other antigen-presenting cells to induce protective immune responses. It has been shown recently that genetic immunization leads to production of recombinant protein(s) in muscle which are delivered to bone marrow-derived antigen-presenting cells. Iwasaki, A.
Abstract
Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.
Description
IMMUNI.ZATION FOR EBOLA VIRUS INFECTION
FIELD OF THE INVENTION
The present invention relates generally to viral vaccines and, more particularly, to Ebola virus vaccines and methods of protecting against disease caused by infection with Ebola virus.
BACKGROUND OF THE INVENTION The Ebola viruses, and the genetically-related Marburg virus, are filoviruses associated with outbreaks of highly lethal hemorrhagic fever in humans and primates in North America, Europe, and Africa. Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996); Peters, CJ. et al , Semin. Virol. 5:147-154 (1994). Ebola viruses are negative-stranded RNA viruses comprised of four subtypes, including those described in the Zaire, Sudan, Reston, and Ivory Coast episodes. Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996). Although several subtypes have been defined, the genetic organization of these viruses is similar, each containing seven linearly arrayed genes. Among the viral proteins, the envelope glycoprotein exists in two alternative forms, a 50-70 kilodalton (kDa) secreted protein of unknown function encoded by the viral genome and a 130 kDa transmembrane glycoprotein generated by RNA editing that mediates viral entry. Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996); Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996). Other structural gene products include the nucleoprotein (NP), matrix proteins VP24 and VP40, presumed nonstructural proteins VP30 and VP35, and the viral polymerase (reviewed in Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996)). Although spontaneous variation of its RNA sequence does occur in nature, there appears to be less nucleotide polymorphism within Ebola subtypes than among other RNA viruses (Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996)), suggesting that immunization may be useful in protecting against this disease. Previous attempts to elicit protective immune responses against Ebola virus using traditional active and passive immunization approaches have, however, not succeeded. Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1 161-1176 (Philadelphia, Lippincott-Raven, 1996); Clegg, J.C.S.
et al., New Generation Vaccines, (eds., Levine, M.M., Woodrow, G.C, Kaper, J.B.& Cobon, G.S.) 749-765 (New York, NY, Marcel Dekker, Inc. 1997); Jahrling, P.B. et al., Arch. Virol. Suppl. 11 :135-140 (1996).
It would thus be desirable to provide a vaccine to protect against disease caused by infection with Ebola virus. It would further be desirable to provide methods of making and using said vaccine.
SUMMARY OF THE INVENTION Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP).
The present invention also provides methods for immunizing a subject against disease caused by infection with Ebola virus comprising administering to the subject an immunoeffective amount of an Ebola virus vaccine. Administration can be by any of the routes normally used for gene therapy. In a preferred method, the Ebola virus vaccine is administered by intramuscular injection. The genetic immunization methods of the present invention provide protective immunity against disease caused by infection with Ebola virus.
Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and subjoined claims and by referencing the following drawings.
Figures 1A and 1 B are photographs showing expression of Ebola virus gene products in eukaryotic plasmid expression vectors. Figure 1A. Expression vectors encoding the indicated viral gene products under regulation of the CMV immediate-early region 1 enhancer and promoter were prepared and transfected into 293 cells as previously described. Manthorpe, M. et al. Hum. Gene. Ther. 4:419-431 (1993); Sambrook, J., Fritch, E.F., & Maniatis, T. Cold Spring Harbor, N.Y. Cold Spring Laboratory Harbor Press, 1994. Cell extracts were prepared and analyzed by Western blot analysis for NP (left) or GP (right) using
relevant rabbit antisera and a secondary antibody, horseradish peroxidase conjugated donkey anti-rabbit IgG of a dilution of 1 :5,000. Incubation with primary antibody was for 30 minutes at room temperature, and for 30 minutes at room temperature with secondary antibody. Immunocomplexes were then detected by chemiluminescence using super signal substrate reagents (Pierce) according to manufacturer's instructions.
Figure 1B. Generation of antibody response in mice immunized with the indicated vectors and analyzed by Western blot for NP, GP, and sGP as shown. Antisera from mice were tested at a dilution of 1 :500 (NP), 1 :50 (GP), or 1 :50 (sGP), respectively, and developed with a secondary antibody (sheep anti-mouse, 1 :5,000, Amersham Life Science) and chemiluminescence as in Figure 1 A. The control vector used for immunization represents the expression vector plasmid with no insert. Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431 (1993).
Figures 2A-2D are graphs showing the immune responses to NP and GP after genetic immunization in mice.
Figure 2A. Splenic lymphocytes from vector or NP-plasmid immunized mice were isolated approximately 6 weeks after the initial immunization and sensitized in vitro for 5 days with 10 U/ml hlL-2. Renca-NP cells sensitized splenocytes from vector-immunized or pCMV-NP immunized mice were used to detect CTL activity at the indicated effectortarget ratios on Renca or Renca-NP cells (left, middle) or with allogeneic effector cells with Renca-NP to show that they are susceptible to lysis (right). Allogeneic effector cells were generated by incubating cells derived from mice with a C57BI/6 background (5x10δ/ml) with irradiated Balb/c spleen cells (5x106/ml) in the presence of IL-2 (20 U/ml) for five days. The chromium release CTL assay with Renca-NP cells was performed in triplicate as previously described. Ohno, T. et al., Gene. Ther. 4:361-366 (1997).
Figure 2B. Balb/C female mice were immunized with the sGP plasmid expression vector and analyzed for their ability to lyse the syngeneic Renca cell line stably expressing GP. Isolation of stable transfectants, confirmation of expression, and CTL assay were performed as described (see. Specific Example, II. Methods). Renca-GP or sGP sensitized splenocytes from pCMV-GP or pCMV-sGP immunized mice were used to determine the specific killing of 51chromium labeled Renca-GP cells at the indicated E/T ratios.
Figure 2C. Mice immunized with GP were analyzed for their ability to lyse a syngeneic CT26 cell stably expressing GP or CT26 vector control transduced line at the indicated E/T ratios.
Figure 2D. Cellular proliferative response in the indicated immunized mice. T cells, enriched or depleted (see, Specific Example, II. Methods), were incubated at
105 cells/ml with sGP condition media (25%). Background was determined with cells incubated in media from control transfected 293 cells and subtracted from proliferation seen in sGP-containing supematants.
Figures 3A-3C are graphs showing immunization with sGP or GP expression plasmids induces T cell responses to sGP in guinea pigs.
Figures 3A-3C. Cell-mediated immunity in guinea pigs was analyzed by performing assays to detect cell proliferation to control or GP antigen (A) or T-cell growth factor production in response to the indicated antigens. The culture supematants containing these antigens were prepared as previously described (Bottomly, K. et al., Measurement of human and murine interleukin 2 and interleukin 4. in Current Protocols in Immunology, (eds., Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M.& Strober, W.) 6.3.1-6.3.12 (New York, John Wiley & Sons, Inc. 1992); Arai, H. et al., Nat. Med. 3:843-848 (1997)), and included at a final concentration of 10% (volume/volume). In A, cell numbers refer to the concentration of spleen cells per ml in the 3H-thymidine proliferation assay. In B, supematants from A, harvested at the time of the peak proliferative response to sGP, were incubated with primary guinea pig T cells maintained in 200 U/ml of human IL-2. The percent maximal response refers to the magnitude of stimulation in response to the indicated stimuli relative to supematants from 24 hour concanaval (in A-stimulated cells (2 μg/ml)). The requirement of T lymphocytes in guinea pig spleen cells for the proliferative response to sGP, performed as described in Specific Example, II. Methods, is shown (C).
Figures 4A-4F are photographs showing the immunohistochemical analysis of Ebola virus antigens in liver, lung, and spleen from representative protected (GP- animal 3) or infected (vector-animal 2) guinea pigs.
Figures 4A-4F. Magnification: liver, 40x; lung, 20x; spleen, 20x.
Figure 5 is a schematic of the plasmid pVR 1012-GP(IC) (Ivory Coast strain of GP, SEQ ID NO: 1 ).
Figure 6 is a schematic of the plasmid pVR 1012-GP(S) (Sudan strain of GP, see SEQ ID NO: 2).
Figure 7 is a schematic of the plasmid pVR 1012-GP(Z) (Zaire strain of GP, see SEQ ID NO: 3).
Figure 8 is a schematic of the plasmid pVR 1012-sGP(Z) (Zaire strain of sGP, see SEQ ID NO: 4). Figure 9 is a schematic of the plasmid pVR 1012-NP.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Ebola virus vaccines are provided comprising a nucleic acid molecule encoding an Ebola viral protein operatively-linked to a control sequence in a pharmaceutically acceptable carrier. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP).
The present invention further includes vaccines comprising nucleic acid molecules encoding Ebola viral proteins other than GP, sGP, and NP, e.g., other structural gene products which elicit protective immunity from disease caused by infection with Ebola virus. The nucleic acid molecules of the vaccines of the present invention encode structural gene products of any Ebola viral strain including the Zaire, Sudan, Ivory Coast and Reston strains. Nucleic acid molecules encoding structural gene products of the genetically-related Marburg virus strains may also be employed. Moreover, the nucleic acid molecules of the present invention may be modified, e.g., the nucleic acid molecules set forth herein may be mutated, as long as the modified expressed protein elicits protective immunity from disease caused by infection with Ebola virus. For example, the nucleic acid molecule may be mutated so that the expressed protein is less toxic to cells. The present invention also includes vaccines comprising a combination of nucleic acid molecules. For example, and without limitation, nucleic acid molecules encoding GP, sGP and NP of the Zaire, Sudan and Ivory Coast Ebola strains may be combined in any combination, in one vaccine composition. The present invention also provides methods for immunizing a subject against disease caused by infection with Ebola virus comprising administering to the subject an immunoeffective amount of an Ebola virus vaccine. Methods of making and using Ebola virus vaccines are also provided by the present invention including the preparation of pharmaceutical compositions.
As referred to herein, the term "encoding" is intended to mean that the subject nucleic acid may be transcribed in a cell, e.g., when the subject nucleic acid is linked to appropriate control sequences such as a promoter in a suitable vector (e.g., an expression vector) and the vector is introduced into a cell. The nucleic acid molecules of the present invention may be DNA molecules, cDNA molecules or RNA molecules, and are preferably cDNA molecules. The term "operatively-linked" as used herein refers to functional linkage between a nucleic acid expression control sequence (such as a promoter) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence. Expression control sequences are known to those skilled in the art (see, e.g., Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990)). Vectors which contain both a promoter and a cloning site to which an inserted piece of nucleic acid is operatively-linked to the promoter, are well known in the art and are generally referred to herein as "expression vectors" or "expression vector plasmids". Preferably, these vectors are capable of transcribing nucleic acid in vitro and in vivo. A preferred vector is the cytomegalovirus (CMV) expression vectorwhich directs high levels of gene expression in muscle.
Nucleic acid molecules which hybridize under stringent conditions to the nucleic acid molecules described herein are also within the scope of the present invention. As will be appreciated by those skilled in the art, multiple factors are considered in determining the stringency of hybridization including species of nucleic acid, length of nucleic acid probe, Tm (melting temperature), temperature of hybridization and washes, salt concentration in the hybridization and wash buffers, aqueous or formamide hybridization buffer, and length of time for hybridization and for washes. An example of stringent conditions are DNA-DNA hybridization with a probe greater than 200 nucleotides in 5 x SSC, at 65°C in aqueous solution or 42°C in formamide, followed by washing with 0.1 x SSC, at 65°C in aqueous solution. (Other experimental conditions for controlling stringency are described in Maniatis, T. et al., Molecular Cloning: a Laboratory Manual, Cold Springs Harbor Laboratory, Cold Springs, N.Y. (1982) at pages 387-389 and Sambrook, J. et al., Molecular Cloning: a Laboratory Manual, Second Edition, Volume 2, Cold Springs Harbor Laboratory, Cold Springs, N.Y., at pages 8.46-8.47 (1989)).
It will be appreciated that administration of the vaccines of the present invention can be by any of the routes normally used for gene therapy. In a preferred
method, administration is by intramuscular injection, however, other procedures for transfecting cells may also be employed, such as transfection using calcium phosphate coprecipitation, liposome-mediated transfection, plasmid and viral vector- mediated transfection and DNA protein complex-mediated transfection. Viral vector- mediated transfection includes, without limitation, the use of retroviral, replication- deficient retroviral, adenoviral and adeno-associated viral vectors. Cells transfected by the vaccines in the context of ex vivo gene therapy can also be administered.
It will be appreciated that more than one route of administering the vaccines of the present invention may be employed either simultaneously or sequentially (e.g., boosting). In addition, the vaccines of the present invention may be employed in combination with traditional immunization approaches such as employing protein antigens, vaccinia virus and inactivated virus, as vaccines. Thus, in one embodiment, the vaccines of the present invention are administered to a subject (the subject is "primed" with a vaccine of the present invention) and then a traditional vaccine is administered (the subject is "boosted" with a traditional vaccine). In another embodiment, a traditional vaccine is first administered to the subject followed by administration of a vaccine of the present invention. In yet another embodiment, a traditional vaccine and a vaccine of the present invention are co-administered.
Immunogenicity may be significantly improved if the vaccines of the present invention are co-administered with an immunostimulatory agent or adjuvant. Adjuvants enhance immunogenicity but are not necessarily immunogenic themselves. Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Adjuvants may thus be employed to enhance the immunogenicity of the vaccines of the present invention, as well as the immunogenicity of traditional vaccines. Suitable adjuvants are well known to those skilled in the art and include, without limitation, aluminum phosphate, aluminum hydroxide, QS21 , Quil A, derivatives and components thereof, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, polyphosphazene, a lipoprotein, ISCOM matrix, DC-Chol, DDA, and other adjuvants and bacterial toxins, components and derivatives thereof.
The vaccines of the present invention may also be co-administered with cytokines to further enhance immunogenicity. The cytokines may be administered by methods known to those skilled in the art, e.g., as a nucleic acid molecule in plasmid form or as a protein or fusion protein.
Upon inoculation with a pharmaceutical composition as described herein, the immune system of the host responds to the vaccine by producing antibodies, both secretory and serum, specific for Ebola virus proteins. As a result of the vaccination, the host becomes at least partially or completely immune to Ebola virus infection, or resistant to developing moderate or severe disease caused by Ebola virus infection. Although Ebola virus infection and disease caused thereby are discussed in detail herein, it will be appreciated that the vaccines and methods of the present invention may be employed to immunize a subject against hemorrhagic fever generally, such as that caused by infection by the genetically-related Marburg virus. Pharmaceutical compositions comprising the nucleic acid molecules encoding
Ebola viral proteins described herein, either alone or in combination, and a pharmaceutically acceptable carrier, are also provided by the present invention. As used herein, the phrase "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as those suitable for parenteral administration, such as, for example, by intramuscular, intraarticular (in the joints), intravenous, intradermal, intraperitoneal, and subcutaneous routes. Examples of such formulations include aqueous and non-aqueous, isotonic sterile injection solutions, which contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non- aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the vaccine dissolved in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the vaccine, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; (d) suitable emulsions; and (e) polysaccharide polymers such as chitians. The vaccine, alone or in combination with other suitable components, may also be made into aerosol formulations to be administered via inhalation, e.g., to the bronchial passageways. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
Suitable formulations for rectal administration include, for example, suppositories, which consist of the vaccine with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a
combination of the vaccine with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the recipient, e.g., the patient. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules or vials and may be prepared by any method known in the art.
Pharmaceutical compositions comprising any of the nucleic acid molecules encoding Ebola viral proteins of the present invention are useful to immunize a subject against disease caused by Ebola virus infection. Thus, this invention further provides methods of immunizing a subject against disease caused by Ebola virus infection, e.g., hemorrhagic fever, comprising administering to the subject an immunoeffective amount of a pharmaceutical composition of the invention. This subject may be an animal, for example a mammal, such as a primate or preferably a human. The vaccines of the present invention are also suitable for veterinary immunization. The vaccines of the present invention comprising nucleic acid molecules encoding Ebola virus structural gene products from the Reston strain, which is known to infect animals, are particularly useful in such veterinary immunization methods. The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, immunogenic and protective. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the immune system of the individual to synthesize antibodies, and, if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and may be monitored on a patient-by-patient basis. However, suitable dosage ranges are readily determinable by one skilled in the art and generally range from about 300 μg to about 4-5 mg. The dosage may also depend, without limitation, on the route of administration, the patient's state of health and weight, and the nature of the formulation.
Methods of immunizing a subject against multiple strains of Ebola virus are further provided herein. The nucleic acid molecules encoding Ebola viral proteins of the present invention may be combined with nucleic acid molecules encoding other viral proteins of other virus strains to achieve protection against multiple strains of
Ebola virus. Typically the vaccines will be in an admixture and administered simultaneously, but may also be administered separately.
In some instances it may be desirable to combine the Ebola virus vaccines of the present invention with vaccines which induce protective responses to other agents, particularly other viruses. For example, the vaccine compositions of the present invention can be administered simultaneously, separately or sequentially with other genetic immunization vaccines such as those for influenza (Ulmer, J.B. et al., Science 259:1745-1749 (1993); Raz, E. et al., PNAS (USA) 91 :9519-9523 (1994)), malaria (Doolan, D.L. et al., J. Exp. Med. 183:1739-1746 (1996); Sedegah, M. et al., PNAS (USA) 91 :9866-9870 (1994)), and tuberculosis (Tascon, R.C. et al., Nat Med. 2:888-892 (1996)).
It will also be appreciated that single or multiple administrations of the vaccine compositions of the present invention may be carried out. For example, subjects who are particularly susceptible to Ebola virus infection may require multiple immunizations to establish and/or maintain protective immune responses. Levels of induced immunity can be monitored by measuring amounts of neutralizing secretory and serum antibodies, and dosages adjusted or vaccinations repeated as necessary to maintain desired levels of protection.
This invention also provides kits comprising the vaccines of the present invention. For example, kits comprising a vaccine and instructions for use are within the scope of this invention.
The vaccines and methods of the present invention evoke a protective immune response and do not lead to immunopotentiation or exacerbated disease. The vaccines lack transmissibility, are genetically stable and induce protective levels of humoral and cell-mediated immunity.
In order to more fully demonstrate the advantages arising from the present invention, the following example is set forth. It is to be understood that the following is by way of example only and is not intended as a limitation on the scope of the invention. SPECIFIC EXAMPLE
I. RESULTS
Immune response to viral gene products in mice. To characterize immune responses to selected Ebola virus proteins, eukaryotic expression vector plasmids were injected into mice. The cytomegalovirus (CMV) immediate early region 1 enhancer was used to stimulate transcription because it directs high levels of gene
expression in muscle. Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431 (1993). cDNAs encoding an abundant structural protein, the major viral nucleocapsid phosphoprotein (NP), the secreted glycoprotein (sGP), or the membrane-associated glycoprotein (GP) were inserted. Alternative forms of GP were chosen because it had been postulated that the transmembrane protein contained a protein sequence motif also found in oncogenic retroviruses that might suppress immune responses. Burkreyev, A.A. et al., FEBS. Lett. 323:183-187 (1993); Cianciolo, G.J. et al., Science 230:453-455 (1985); Harris, D.T. et al., J. Immunol. 138:889-894 (1987); Volchkov, V.E. et al., FEBS. Lett. 305:181-184 (1992); Sanchez, A. et al., Virus. Res. 29:215- 240 (1993). Expression of the relevant proteins was confirmed after transfection of the human renal epithelial cell line, 293, by immunoblotting with antisera to these gene products (Fig. 1A). For NP, the expected full-length 104 kDa protein normally produced by the virus was seen, together with lower molecular weight species likely generated from truncated protein or degradation products described previously. Sanchez, A. et al., Virology 170:81-91 (1989). Similarly, expression of sGP and GP revealed a heterogeneous pattern whose sizes correlated with the expected products of cleavage or post-translational carbohydrate modification. Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996).
These plasmids were injected into mice to characterize their ability to induce humoral and cellular immune responses to the relevant viral proteins. Three injections, each with 50 μg of plasmid DNA in saline (100 //I), were performed at two- week intervals in Balb/C female mice (6-8 week old, Charles River). Serum from immunized recipients were examined for antibody responses. An antibody response to the viral NP gene product was readily detectable (Fig. 1 B), with titers of ≥ 1 :16,000 by Western blot analysis. The titer of antibody induced in response to injection with plasmids encoding the viral glycoproteins was lower. After immunization with GP, no antibody was detectable by Western blotting, while immunization with sGP induced an antibody response (Fig. 1 B). The more sensitive ELISA (Ksiazek, T.G., Lab. Anim. 20:34-46 (1991 ); Ksiazek, T.G. et al., J. Clin. Microbiol. 30:947-950 (1992)) did allow detection of antibodies to both GP and sGP at titers of 1 :400 and 1 :1 ,200, respectively. Cytolytic T cell (CTL) responses to these viral proteins were analyzed next. Despite the substantial humoral immune response to NP, minimal CTL activity was detected against syngeneic cells expressing this viral protein (Fig. 2A). In contrast, genetic immunization with sGP, which elicited a weaker antibody response, induced a marked cytolytic T cell response to cells expressing GP (Fig. 2B).
Immunization with the GP plasmid also induced a significant CTL response to GP (Fig. 2C). These data suggested that both the secreted and transmembrane form of the protein could be processed for antigen presentation and the transmembrane form was a target for recognition by these cytolytic T cells. Finally, antigen-specific T cell proliferation to sGP was also observed in GP and sGP but not plasmid control injected mice (Fig. 2D).
The ability of antibodies detected in mouse sera after immunization to neutralize virus was tested in an in vitro infection assay. McCormick, J.B. et al., J. Infect. Dis. 147:264-267 (1983). In no case was neutralization of infectivity observed, even at titers of 1 : 10 (data not shown), despite the documented presence of antibody after NP and sGP immunization by Western blot analysis. Infectivity in vitro was thus not inhibited by Ebola-specific antibodies.
Immune function and viral challenge in guinea pigs. To determine whether the in vivo immune responses could protect against viral infection, virus was adapted to grow in guinea pigs. Though this species is not well-suited to analysis of immune function, infection in adult mice has not been successful. Moreover, infection in guinea pigs, used originally to propagate virus from infected humans, is a well- established animal model for the human disease. Infection gives rise to a syndrome of hemorrhagic fever with levels of virus, organ pathology, and infection of reticuloendothelial and mononuclear cells comparable to humans. Bowen, E.T.W. et al., Lance. 1 :571-573 (1977).
Two groups of immunized guinea pigs were studied. Animals were injected intramuscularly with the relevant expression vector plasmids, and the response to infection in groups immunized with either sGP, GP, NP, or control plasmids was observed. In the first group, animals were challenged within 2 months after the initial immunization, at which time the antibody titers were high, ranging from 1 :1 ,600 to >1 :25,000 (Table 1A). In these animals, nearly complete protection from lethal challenge was observed in GP (6/6), sGP (5/6), and NP (4/4) immunized subjects, in contrast to controls (0/6). In a second group, guinea pigs were challenged four months after the initial immunization (Table 1 B). As in the first group, all animals immunized with the control vector succumbed to infection within a week after virus challenge (n=4). In this group, antibody titers were lower, and three of the four guinea pigs immunized with NP succumbed to infection, with the single survivor appearing severely ill after 1 week, in contrast to the protective response with NP at the earlier time point after immunization in Group I. More effective protection was
seen in animals immunized with vector expressing GP, protection was noted in four of five animals challenged, with one survivor appearing weak but surviving the viral challenge. Similarly, three of the five animals immunized with sGP showed no ill effects following viral challenge. Protection in this group again correlated with the ability to sustain an effective immune response to GP or sGP. Together, all guinea pigs immunized with vectors expressing GP or sGP which had titers greater than 1 :5,120 were resistant to infection (11/11 ) compared to 0/10 controls (p=0, by Fisher's exact test). Twelve of fourteen animals with antibody titers > 2,560 survived viral challenge compared to controls (p=.00003, by Fisher's exact test). Similar to immunized mice, guinea pigs injected with GP or sGP plasmids were able to generate cell-mediated immune responses to the viral glycoprotein in addition to the antibody response. These responses were antigen-specific and T cell-dependent, as detected in sGP antigen-dependent spleen cell proliferation and T-cell growth factor assays (Fig. 3A-C). Thus, the ability to generate and sustain significant cellular immune responses in vivo correlated with protection from infection. Though antibody titer correlated with protection, cell-mediated immunity appeared necessary for protection since passive transfer of antibody to GP does not confer protection (Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1 176 (Philadelphia, Lippincott-Raven, 1996); Jahrling, P.B. et al., Arch. Virol. Suppl. 1 1 :135-140 (1996)) and antisera from protected guinea pigs did not inhibit virus replication in vivo (n=3) or at a 1 :10 dilution in vitro (data not shown). Since the Hartley guinea pig to which the virus has been adapted for growth is outbred, cellular adoptive transfer studies could not be performed. TABLE 1 - Group I
Plasmid Subject ELISA(Pre) ELISA(Posf) Viral Ae Survival
GP 1 >1 :25,600 1 :12,800 Yes
GP 2 >1:25,600 1:25,600 Yes
GP 3 >1:25,600 1 :25,600 Yes
GP 4 1 :25,600 1 :6,400 Yes
GP 5 1:25,600 1:12,800 Yes
GP 6 1 :25,600 1 :25,600 Yes
SGP 1 1 :12,800 1 :25,600 Yes
SGP 2 1:6,400 1 :25,600 Yes
SGP 3 1:6,400 1:25,600 Yes
SGP 4 1:25,600 1 :25,600 - Yes
SGP 5 >1 :25,600 1:12,800 - Yes
SGP 6 1:1,600 Negative + No
NP 1 1 :12,800 >1 :25,600 - Yes
NP 2 >1 :25,600 1 :25,600 - Yes
NP 3 1 :12,800 1 :12,800 - Yes
NP 4 1 :25,600 1:25,600 - Yes
Vector alone 1 Negative Negative + No
Vector alone 2 Negative n.d. + No
Vector alone 3 Negative Negative + No
Vector alone 4 Negative Negative + No
Vector alone 5 Negative n.d. + No
Vector alone 6 Negative n.d. + No
Guinea pigs were immunized on days 1, 14, 28, 42, and challenged on day 62.
TABLE 1 - Group II
Plasmid Subject ELISAfPreϊ ELISA(Post) Viral Ag Survival
GP 1 1 :2,560 n.d. +/f No
GP 2 1:5,120 1:10,240 - Yes
GP 3 1:10,240 1 :10,240 - Yes
GP 4 1:1,280 n.d. +/f No
GP 5 1 :5,120 1 :20,480 - Yes (ill)
SGP 1 1 :2,560 n.d. + No
SGP 2 1 :10,240 1:5,120 +/f Yes
SGP 3 1 :10,240 1 :81,920 - Yes
SGP 4 1:2,560 1:5,120 - Yes
SGP 5 1 :640 n.d. + No
NP 1 n.d. n.d. + No
NP 2 n.d. n.d. + No
NP 3 n.d. n.d. + No
NP 4 n.d. Negative + Yes (ill)
Vector alone 1 Negative n.d. + No
Vector alone 2 Negative n.d. + No
Vector alone 3 Negative n.d. + No
Vector alone 4 Negative n.d. + No
Guinea pigs were immunized on days 1 , 14, 42, and 112 and challenged on day 122. n.d.=not done. Viral ag denotes presence of virus determined by immunohistochemistry (30) performed on spleen, liver, lung, kidney, and heart tissues; "+" = widespread systemic involvement of the mononuclear phagocyte system and to a lesser extent endothelial and parenchymal cells; "+/f" = focal involvement (seen in the spleen of SGP #2, the liver and spleen of GP #1 , and the lung of GP#4) where rare sites of anti-Ebola antibody staining were detected.; "-" = no Ebola virus antigen detected in tissues. ELISA determinations made prior to viral challenge (Pre) or at least 7 days after (Post) infection, respectively.
The surviving NP immunized animal (4) was found to have significant levels of virus in major organs by immunohistochemistry, and more than 5 logs of virus was detected in the serum and spleen, in contrast to GP and sGP animals where no virus was detected.
Histopathologic analysis of infection in immunized guinea pigs.
Pathologic analysis revealed widespread tissue necrosis and dissemination of virus by immunohistochemistry, similar to human disease. Virus load correlated with susceptibility to infection with titers of > 105 in infected animals compared to undetectable levels in immunized survivors. In infected animals, the liver, lung, and spleen showed evidence of significant viral antigen by immunohistochemistry (Fig. 4, Table 1), and both reticuloendothelial and mononuclear phagotic involvement was observed.
Determination of antibody response in animals which survived virus challenge revealed increases in the immune response to viral proteins when initial titers were lower (Table 1 ). Less consistent increases in antibody titers were observed in the NP immunized animals. These data suggest that Ebola virus infection may stimulate immunity in survivors of a viral challenge when immune responses are not optimal. II. METHODS Plasmids. Plasmids containing the GP, sGP, or NP cDNAs (Sanchez, A. et al., Virus. Res. 29:215-240 (1993), Genbank) were used to subclone the relevant inserts into CMV expression vectors which utilized the bovine growth hormone polyadenylation sequence. Manthorpe, M. et a I., Hum. Gene. Ther. 4:419-431 (1993). (see Figures 5-9 and SEQ ID NOS: 1-4). Briefly, for GP, plasmid pGEM-3Zf(-)-GP was digested with EcoR I, treated with the Klenow fragment of E. coli DNA polymerase, and digested with BamH I. The GP fragment was then inserted into the pCMV expression vector plasmid digested with BamH I, Klenow fragment and Bgl II. For sGP, the plasmid pCRII-sGP was digested with EcoR I, treated with Klenow
enzyme, and the resulting fragment inserted into the BamH l/Bgl II CMV plasmid which had been incubated with Klenow fragment, calf intestinal phosphatase (CIP), then phenol chloroform extract. For the NP expression vector, plasmid pSP64-NP2 (Sanchez, A. et al., Virology 170:81-91 (1989)) was digested with EcoR I, treated with Klenow enzyme, and digested with BamH I. The NP insert was cloned into CMV treated with BamH I, Klenow enzyme, followed by heat inactivation and Bgl II digestion.
Cell lines and transfectants. For stable transfectants, the relevant cDNAs were inserted into a CMV expression plasmid containing a neomycin resistant gene, pCMV-neo (H. Arai, unpublished data), which was digested with Xba I, and treated with CIP and Klenow enzyme. The EcoR I/ BamH I GP fragment from pGEM-3Zf(-)- GP, the EcoR I sGP fragment from pCRII-SGP, or the EcoR l/BamH I NP fragment from pSP64-NP2 was treated with Klenow enzyme and ligated to this plasmid backbone. These vectors were transfected into Renca or CT26 which was syngeneic to Balb/C mice using calcium phosphate and selected in 0.7 or 1 mg/ml G418 for 2-6 weeks. Expression of GP, sGP, or NP from these vectors in Renca or CT26 cells was also confirmed by Western blot analysis (data not shown).
Cell proliferation assay. Spleen cells from male Hartley guinea pigs or Balb/C female mice (8-10 weeks) immunized with the indicated plasmid expression vectors were incubated with sGP or vector control supematants (25% volume:volume) from transfected 293 cells at the indicated cell concentrations. T cell depletion was performed using the CT5 monoclonal antibody (Tan, B.T.G. et al., Hybridoma 4:115- 124 (1985)) (Biosource, Cama llo, CA) for guinea pigs or anti-Thy 1.2 antibody in the mouse using immunomagnetic microbeads (Miltenyi Biotec, Inc., Auburn, CA). Viral challenge in guinea pigs. Animals were immunized by injection of 100 μ\ (0.5 mg/ml) in each hind leg (two injections at each time point) with the indicated plasmid expression vectors. Animals were challenged by inoculation with a stock of Ebola virus (Zaire, 1976) that had been passaged once in vero E6 cells and serially passaged by intraperitoneal injection of spleen homogenates in Hartley guinea pigs seven times. Immunized guinea pigs were injected intrapehtoneally with 0.5 ml of a 1 :1 ,000 dilution of spleen cell homogenate in Hank's balanced salt solution 122 days after the initial plasmid DNA injection (1000 pfu). Survival was determined 10 days later at which times animals were sacrificed for serologic and pathologic analysis. ELISA, enzyme-linked immunosorbent assay (Volchkov, V.E. et al., FEBS. Lett. 305:181-184 (1992); Sanchez, A. et al., Virus. Res. 29:215-240 (1993)) on infected
cell supematants and enriched viral extracts containing GP, sGP, or NP were performed as previously described. III. DISCUSSION
Following the initial report that injection of plasmid DNA into muscle could direct the synthesis of recombinant proteins (Wolff, J.A. et al., Science 247:1465-1468 (1990)), the suggestion was made that this gene transfer approach may be useful for vaccination and was termed genetic immunization. Tang, D.C et al., Nature 356: 152- 154 (1992). This approach has been applied to different infectious diseases, including influenza (Ulmer, J.B. et al., Science 259:1745-1749 (1993); Raz, E. et al., PNAS (USA) 91 :9519-9523 (1994)), malaria (Doolan, D.L. et al., J. Exp. Med. 183:1739- 1746 (1996); Sedegah. M. et al. , P/v"AS(X;SA> 91 :9866-9870 (1994)), and tuberculosis (Tascon, R.C. et al., Nat. Med. 2:888-892 (1996)) and has also been used to modulate antibody and cell-mediated immune responses in autoimmune and allergic diseases. Raz, E. et al., PNAS (USA) 90:4523-4527 (1993); Waisman, A. et al., Nat. Med. 2:899-905 (1996); McCormick, J.B. et al., J. Infect. Dis. 147:264-267 (1983); Border, W.A. et al., Nat. Med. 1 :1000-1001 (1995).
The immune response to selected Ebola virus proteins after genetic immunization in mice was analyzed and their ability to protect against lethal infection in a susceptible animal model, the guinea pig, was tested. The immune analyses performed in different species suggest similar patterns of response, though the specific peptides which may be recognized by the immune system to confer protection in the guinea pig could differ from the mouse. Because the principles of MHC antigen presentation and recognition apply broadly across species (Monaco, J.J., Immunol. Today 13:173-179 (1992); Jorgensen, J.L. et al., Annu. Rev. Immunol. 10:835-873 (1992); Zinkemagel, R.M. et al., Immunol. Today 18:14-17 (1997)), the finding that protection was observed in different members of an outbred strain and that similar immune responses were seen in different species is not unexpected and suggests that this approach may be applicable to humans.
Immunization with plasmids encoding distinct viral proteins induced different antibody and cytolytic T cell responses. The broadest immune response was conferred by GP and sGP, which induced both cellular and humoral immunity to the membrane-associated GP. In guinea pigs challenged with doses of virus that are otherwise lethal, sGP provided nearly equivalent protection to GP, with no significant difference between these groups. The ability of vectors expressing GP to confer immunity may be explained by the generation of lower molecular weight degradation
products (Fig. 1 B) which could provide sufficient protein for antigen presentation to induce detectable, cellular, and humoral immune responses in guinea pigs.
Despite the fact that plasmid DNA injection has been shown to affect the immune response to different antigens in infectious and autoimmune diseases, the ability of individual gene products to protect against disease in vivo is not readily predictable. In particular, the rapid rates of Ebola virus replication and the poor immunogenicity of its proteins had previously rendered it resistant to immune interventions. Several attempts to confer protection with passive transfer of immunoglobulin were unsuccessful (Peters, CJ. etal., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996); Jahrling, P.B. etal. , Arch. Virol. Suppl. 11 :135- 140 (1996)), in agreement with the finding set forth herein that antisera from protected animals fails to neutralize virus replication in vitro. Previous studies using formalin- fixed virus or purified viral proteins for immunization have also not proven effective. Peters, CJ. et al., Filoviridae: Marburg and Ebola Viruses, in Fields Virology, (eds., Fields, B.N., Knipe, D.M.& Howley, P.M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996); Clegg, J.C.S. & Sanchez, A. Vaccines against arenaviruses and filoviruses. in New Generation Vaccines, (eds., Levine, M.M., Woodrow, G.C., Kaper, J.B.& Cobon, G.S.) 749-765 (New York, NY, Marcel Dekker, Inc. 1997). It is likely that traditional immunization approaches using protein antigens, vaccinia virus, or inactivated virus do not allow for appropriate uptake and presentation of viral antigens by dendritic or other antigen-presenting cells to induce protective immune responses. It has been shown recently that genetic immunization leads to production of recombinant protein(s) in muscle which are delivered to bone marrow-derived antigen-presenting cells. Iwasaki, A. et al., J. Immunol. 159:11-14 (1997); Doe, B. et al., PNAS (USA) 93:8578-8583 (1996); Corr, M. et al., J. Exp. Med. 184: 1555-1560 (1996). Synthesis of Ebola glycoprotein after gene transfer apparently allows more efficient processing and presentation and the generation of immune responses not seen with virus or with viral vectors. GP is a large molecule which contains both T and B cell epitopes. Although antibody levels provide a surrogate marker of protection, the fact that passive transfer of antibody did not confer protection implies that immunoglobulin switching and synthesis is reflective of the T helper response to GP. Genetic immunization stimulates T helper cells to generate both CTL and B cell antibody responses to the virus. Although antibody production confirms effective immunization, a productive T cell response, likely involving TH1 cell
stimulation, as shown by the T cell proliferation and CTL assays (Fig. 3), is needed for effective immunity. Taken together, these studies suggest that transcription and translation of viral genes in host cells by genetic immunization induces alternative, more effective, processing and antigen presentation which better stimulates immunity to Ebola virus. Since there are yet no effective antiviral agents, the ability to generate protective immunity by vaccination may prove useful in selected high risk populations, particularly in regions of ongoing outbreaks, and among medical and laboratory personnel exposed to the virus. Although it remains important to identify agents which treat acute infection, genetic immunization may help to limit the spread of this highly lethal infectious disease.
The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying drawings and claims, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims.
All references cited herein are incorporated by reference as if fully set forth.
Claims
1. A pharmaceutical composition comprising a nucleic acid molecule encoding an Ebola virus structural gene product operatively-liked to a control sequence, in a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of Claim 1 , wherein the Ebola virus structural gene product is selected from the group consisting of the transmembrane form of virus glycoprotein, the secreted form of virus glycoprotein, virus nucleoprotein and combinations thereof.
3. The pharmaceutical composition of Claim 1 , wherein the control sequence is a promoter.
4. The pharmaceutical composition of Claim 3, wherein the promoter is the CMV immediate-early region 1 promoter.
5. The pharmaceutical composition of Claim 1 , further comprising an adjuvant.
6. The pharmaceutical composition of Claim 2, wherein the structural gene product is the transmembrane form of virus glycoprotein.
7. The pharmaceutical composition of Claim 2, wherein the structural gene product is the secreted form of virus glycoprotein.
8. The pharmaceutical composition of Claim 2, wherein the structural gene product is virus nucleoprotein.
9. A method of producing a vaccine against disease caused by infection by Ebola virus, comprising the steps of: a) administering the pharmaceutical composition of Claim 1 to a test host to determine an amount and a frequency of administration thereof to elicit a protective immune response in said host; and b) formulating said pharmaceutical composition in a form suitable for administration to a treatable host in accordance with said determined amount and frequency of administration.
10. A vaccine comprising a nucleic acid molecule encoding the transmembrane form of the Ebola virus glycoprotein operatively-linked to a control sequence, in a pharmaceutically acceptable carrier.
11. The vaccine of Claim 10, wherein the control sequence is a promoter.
12. The vaccine of Claim 1 1 , wherein the promoter is the CMV immediate- early region 1 promoter.
13. The vaccine of Claim 10, further comprising an adjuvant.
14. A vaccine comprising a nucleic acid molecule encoding the secreted form of the Ebola virus glycoprotein operatively-linked to a control sequence, in a pharmaceutically acceptable carrier.
15. The vaccine of Claim 14, wherein the control sequence is a promoter.
16. The vaccine of Claim 15, wherein the promoter is the CMV immediate- early region 1 promoter.
17. The vaccine of Claim 14, further comprising an adjuvant.
18. A vaccine comprising a nucleic acid molecule encoding the Ebola virus nucleoprotein operatively-linked to a control sequence, in a pharmaceutically acceptable carrier.
19. The vaccine of Claim 18, wherein the control sequence is a promoter.
20. The vaccine of Claim 19, wherein the promoter is the CMV immediate- early region 1 promoter.
21. The vaccine of Claim 18, further comprising an adjuvant.
22. A method of immunizing a subject against hemorrhagic fever comprising the step of administering to the host an immunoeffective amount of the vaccine of any of Claims 10 to 21.
23. The method of Claim 22, wherein the hemorrhagic fever is caused by infection with Ebola virus.
24. The method of Claim 22, wherein the hemorrhagic fever is caused by infection with Marburg virus.
25. The method of Claim 22, wherein the host is a human and administration is by intramuscular injection.
26. The method of Claim 22, wherein the subject receives a second administration of an immunoeffective amount of a vaccine against disease caused by infection by Ebola virus or Marburg virus.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/913,909 US6852324B1 (en) | 1997-12-23 | 1998-12-23 | Immunization for ebola virus infection |
US11/038,933 US20050281844A1 (en) | 1997-12-23 | 2005-01-19 | Immunization for Ebola virus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6865597P | 1997-12-23 | 1997-12-23 | |
US60/068,655 | 1997-12-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/038,933 Division US20050281844A1 (en) | 1997-12-23 | 2005-01-19 | Immunization for Ebola virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999032147A1 true WO1999032147A1 (en) | 1999-07-01 |
Family
ID=22083908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/027364 WO1999032147A1 (en) | 1997-12-23 | 1998-12-23 | Immunization for ebola virus infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1999032147A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000000617A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
WO2001091536A2 (en) * | 2000-06-02 | 2001-12-06 | Genphar, Inc. | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
EP1504112A2 (en) * | 2001-10-01 | 2005-02-09 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
EP1608393A2 (en) * | 2003-03-10 | 2005-12-28 | United States Army Medical Research Institute of Infectious Diseases Department of the Army | Ebola peptides and immunogenic compositions containing same |
WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
US7092633B2 (en) | 2000-11-14 | 2006-08-15 | University Of Texas System Board Of Regents | System and method for configuring optical circuits |
US7736656B2 (en) | 1998-06-29 | 2010-06-15 | The United States Of America As Represented By The Secretary Of The Army | Immunogenic compositions and vaccines for Ebola |
US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
WO2011130379A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
-
1998
- 1998-12-23 WO PCT/US1998/027364 patent/WO1999032147A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
PALESE P, ET AL.: "NEGATIVE-STRAND RNA VIRUSES: GENETIC ENGINEERING AND APPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93, 1 October 1996 (1996-10-01), US, pages 11354 - 11358, XP002918687, ISSN: 0027-8424, DOI: 10.1073/pnas.93.21.11354 * |
SANCHEZ A, ET AL.: "THE VIRION GLYCOPROTEINS OF EBOLA VIRUSES ARE ENCODED IN TWO READING FRAMES AND ARE EXPRESSED THROUGH TRANSCRIPTIONAL EDITING", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93, 1 April 1996 (1996-04-01), US, pages 3602 - 3607, XP002918688, ISSN: 0027-8424, DOI: 10.1073/pnas.93.8.3602 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000000617A3 (en) * | 1998-06-29 | 2001-05-31 | U S Medical Res Inst Of Infect | Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
US7736656B2 (en) | 1998-06-29 | 2010-06-15 | The United States Of America As Represented By The Secretary Of The Army | Immunogenic compositions and vaccines for Ebola |
WO2000000617A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
US6984504B2 (en) | 1998-06-29 | 2006-01-10 | The United States Of America As Represented By The Secretary Of The Army | Ebola virion proteins expressed from venezuelan equine encephalitis (VEE) virus replicons |
US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
WO2001091536A2 (en) * | 2000-06-02 | 2001-12-06 | Genphar, Inc. | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
WO2001091536A3 (en) * | 2000-06-02 | 2002-08-08 | Genphar Inc | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
US6964762B2 (en) | 2000-06-02 | 2005-11-15 | Genphar, Inc. | Composition and method for stimulating immune response to pathogen using complex adenoviral vector |
US7092633B2 (en) | 2000-11-14 | 2006-08-15 | University Of Texas System Board Of Regents | System and method for configuring optical circuits |
US8106026B2 (en) | 2001-10-01 | 2012-01-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
US7635688B2 (en) | 2001-10-01 | 2009-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
US7094598B2 (en) | 2001-10-01 | 2006-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
EP1504112A4 (en) * | 2001-10-01 | 2006-02-08 | Us Health | Development of a preventive vaccine for filovirus infection in primates |
US8106027B2 (en) | 2001-10-01 | 2012-01-31 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
US8124592B2 (en) | 2001-10-01 | 2012-02-28 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
AU2002327049B2 (en) * | 2001-10-01 | 2008-04-03 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
EP1504112A2 (en) * | 2001-10-01 | 2005-02-09 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
US7335356B2 (en) | 2002-08-23 | 2008-02-26 | United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
EP1608393A2 (en) * | 2003-03-10 | 2005-12-28 | United States Army Medical Research Institute of Infectious Diseases Department of the Army | Ebola peptides and immunogenic compositions containing same |
EP1608393A4 (en) * | 2003-03-10 | 2006-12-27 | Us Army Med Res Inst | Ebola peptides and immunogenic compositions containing same |
US8101739B2 (en) | 2004-09-27 | 2012-01-24 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector |
WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
JP2008514203A (en) * | 2004-09-27 | 2008-05-08 | アメリカ合衆国 | Vaccines optimized for protection against Ebola and other viruses |
US9012618B2 (en) | 2004-09-27 | 2015-04-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures |
WO2011130379A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US8524684B2 (en) | 2010-08-09 | 2013-09-03 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US8703735B2 (en) | 2010-08-09 | 2014-04-22 | Sarepta Therapeutics, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US9382536B2 (en) | 2010-08-09 | 2016-07-05 | Sarepta Therapeutics, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US9982261B2 (en) | 2010-08-09 | 2018-05-29 | Sarepta Therapeutics, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Immunization for Ebola virus infection | |
Vanderzanden et al. | DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge | |
JP4198148B2 (en) | Development of preventive vaccine against filovirus infection in primates | |
Rao et al. | Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4+ T cells | |
Hevey et al. | Marburg virus vaccines: comparing classical and new approaches | |
EA010433B1 (en) | Improved adenoviral vectors and uses thereof | |
US20210338804A1 (en) | Vaccine Compositions For Preventing Coronavirus Disease | |
EA021391B1 (en) | Method of raising an immune response, vaccine composition, use thereof and kit | |
US7645455B2 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
WO1999032147A1 (en) | Immunization for ebola virus infection | |
US20030108560A1 (en) | Chimeric filovirus glycoprotein | |
Rosas et al. | Taenia crassiceps cysticercosis: humoral immune response and protection elicited by DNA immunization | |
EP3600399A1 (en) | Methods and compositions for vaccinating against malaria | |
US20050281844A1 (en) | Immunization for Ebola virus infection | |
Toussaint et al. | Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8 | |
US20050070700A1 (en) | Equine arteritis virus vaccine | |
EP3511417A1 (en) | Rift valley fever virus glycoproteins, gn and gc, and their use | |
CN115698295A (en) | Vaccine reagent and inoculation method | |
JP2023526309A (en) | Recombinant Vaccine Against COVID-19 Based on Paramyxovirus Virus Vector | |
Auperin | Construction and evaluation of recombinant virus vaccines for Lassa fever | |
US20140255444A1 (en) | Compositions and methods for treating ebola virus infection | |
CA2283490A1 (en) | Fiv vaccine | |
JP2010528603A (en) | Raccoonpox virus expression gene of feline antigen | |
US7238672B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
Ormonde | Characterization of the matrix proteins of the fish rhabdovirus, infectious hematopoietic necrosis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09913909 Country of ref document: US |